Underutilization of palliative care in advanced COPD and heart failure: associations, disparities, and the role of specialists
Therapeutic Advances in Respiratory Disease · Published 2025-08-01 · DOI 10.1177/17534666251364056
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1177/17534666251364056
Abstract
Background: Palliative care is essential for managing advanced chronic illnesses (ACI) but remains underused. Objectives: We aimed to evaluate the prevalence, associations, and outcomes of palliative care utilization (PCU) in patients with ACIs. Design: A prospective observational questionnaire-based study. Methods: The study included hospitalized patients with severe COPD ( n = 53), advanced heart failure (HF; n = 56), or metastatic malignancy ( n = 57). Participants were interviewed about their demographics, health status, PCU, and end-of-life decision-making. Results: A total of 166 subjects were included (median age: 77 years; 41% females), with a 1-year median of 2 hospital admissions. Subjects with COPD and HF had low rates of PCU compared to those with malignancy (6% and 11% vs 39%, p < 0.01). PCU occurred exclusively in patients who had visited a specialist (cardiologist, pulmonologist, or oncologist) before study inclusion. Patients with PCU were more aware of advance directives (71% vs 38%), signed advanced orders (23% vs 3%), and shared their end-of-life decisions with others (71% vs 29%). These differences remained significant after adjustment for prior specialist visits. Independent associations with PCU were self-identifying as non-religious (adjusted OR 3.41, 95% CI 1.2–9.9), above high-school education (AOR 2.84, 95% CI 1.1–7.3), and chronic pain (aOR 2.81, 95% CI 1.11–7.14), while COPD showed the opposite (aOR 0.25, 95% CI 0.07–0.96). Conclusion: Palliative care utilization is alarmingly low among patients with HF and COPD despite significant symptom burden. Specialists should advocate for PCU as their involvement could enhance end-of-life care planning, improve patient outcomes, and address current gaps in care.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2025
Related articles
- What factors predict severity of palliative care symptoms and concerns in COPD in South Africa? A cross-sectional study · Palliative Care and Social Practice · 2026 · Cites or is cited by this article
- Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of “aged” people with cystic fibrosis · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- The effectiveness of the AI-based RehabLung mobile rehabilitation system on cardiopulmonary function and user satisfaction in lung cancer patients undergoing thoracic surgery: a protocol for a two-arm randomized clinical trial · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Spontaneous pneumothorax-associated with genetic disorders · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Effects of dual bronchodilation on right ventricular function and troponin-I in newly diagnosed, moderate-to-severe chronic obstructive pulmonary disease: a prospective real-world observational study · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Social risk factors in patients with cystic fibrosis: impacts on exacerbations, lung function, and BMI · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Tislelizumab in conjunction with chemotherapy for the treatment of nasal metastasis from lung squamous cell carcinoma: a case report and literature review · Therapeutic Advances in Respiratory Disease · 2025 · Same journal